Neos Therapeutics (NEOS) Reports Q4 Loss of $1.14/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Neos Therapeutics (NEOS) Reports Q4 Loss of $1.14/Share

Neos Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results

March 14, 2017 7:00 AM EDT

DALLAS and FORT WORTH, Texas, March 14, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today reported financial results for the fourth quarter and full year ended December 31, 2016 and provided a business update.     

The strong prescription growth of Adzenys XR-ODT speaks to the growing demand for this first ever extended release ODT treatment option for patients with ADHD, and the success of our launch. Some... More